Nexalin Technology Regains Compliance with Nasdaq Minimum Bid Price Requirement; Nasdaq Hearings Panel Grants Request for Continued Listing

Company remains focused on its transition toward commercial revenue generation and the advancement of its U.S. clinical programs Company remains focused on its transition toward commercial revenue generation and the advancement of its U.S. clinical programs